Colchicine as A Potential Therapy in Hepatocellular Carcinoma: A Review
Background: Liver cancer is the seventh most common cancer and the fourth leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is a challenging disease to treat and has a poor prognosis. Colchicine is an old drug that was recently found to have anticancer activities towards several cancer cells. This article aimed to review the potential properties of colchicine as chemotherapy for HCC.
Methods: The literature review was done by searching databases from PubMed, Cochrane, and ProQuest from June 4th to 26th, 2021. Full-text articles were searched by literature search strategies. The articles were screened by abstract and title. Studies that met the criteria were screened for full text.
Results: Forty-six articles were identified, seven articles were screened for titles and abstracts, and three articles were excluded owing to full-text unavailability. Four articles were reviewed.
Conclusions: The potential of colchicine as a preventive therapy in HCC needs to be further explored, and additional tests need to be done, especially in vivo. Larger population studies should also be done to evaluate the safety, usefulness, and feasibility of colchicine, especially in HCC.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
Petrick JL, McGlynn KA. The changing epidemiology
of primary liver cancer. Curr Epidemiol reports. 2019;6(2):104.
Raza A, Sood GK. Hepatocellular carcinoma review:
Current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115.
Wu S, Wang Y, Sun L, et al. Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma. BMC Cancer. 2011;11(1):413.
Lin ZY, Kuo CH, Wu DC, Chuang WL. Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J Med Sci. 2016;32(2):68–73.
Lin ZY, Wu CC, Chuang YH, Chuang WL. Anti-cancer
mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci. 2013 Sep 3;93(8):323–8.
McLoughlin EC, O’Boyle NM. Colchicine-Binding Site
Inhibitors from Chemistry to Clinic: A Review. Pharm. 2020;13(1):8.
Krinsky G, Shanbhogue K. Proliferative versus Nonproliferative Hepatocellular Carcinoma: Clinical
and Imaging Implications. Radiology. 2021;300(3):583–5.
Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616–30.
Lin ZY, Yeh ML, Huang CI, et al. Potential of novel
colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. Kaohsiung J Med Sci. 2021;37(7):616–23.
EASL Clinical Practice Guidelines: Management of
hepatocellular carcinoma. J Hepatol. 2018;69(1):182–
Dudkiewicz I, Brosh T, Perelman M, Salai M. Colchicine inhibits fracture union and reduces bone strength—in vivo study. J Orthop Res. 2005;23(4):877–81.
Bhattacharya S, Das A, Datta S, et al. Colchicine induces autophagy and senescence in lung cancer cells at clinically admissible concentration: potential use of colchicine in combination with autophagy inhibitor in cancer therapy. Tumor Biol. 2016;37(8):10653–64.
Lu Y, Chen J, Xiao M, et al. An overview of tubulin inhibitors that interact with the colchicine binding
site. Pharm Res. 2012;29(11):2943–71.
Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs
That Target Dynamic Microtubules: A New Molecular
Perspective. Med Res Rev. 2011;31(3):443.
Sivakumar G. Colchicine Semisynthetics: Chemotherapeutics for Cancer? Curr Med Chem.
Cocco G, Chu DCC, Pandolfi S. Colchicine in clinical
medicine. A guide for internists. Eur J Intern Med.
Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine
poisoning: the dark side of an ancient drug. Clin Toxicol. 2010;48(5):407–14.
Imazio M, Bobbio M, Cecchi E, et al. Colchicine in
Addition to Conventional Therapy for Acute Pericarditis. Circulation. 2005;112(13):2012–6.
Imazio M, Brucato A, Trinchero R, et al. Colchicine
for pericarditis: hype or hope? Eur Heart J. 2009;30(5):532–9.
Kallinich T, Haffner D, Niehues T, et al. Colchicine
Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and C o n s e n s u s S t a t e m e n t . P e d i a t r i c s . 2007;119(2):e474–83.
Rubin CI, Atweh GF. The role of stathmin in the
regulation of the cell cycle. J Cell Biochem. 2004;93(2):242–50.
Maldonado EN, Patnaik J, Mullins MR, Lemasters
JJ. Free Tubulin Modulates Mitochondrial Membrane
Potential in Cancer Cells. Cancer Res. 2010;70(24):10192.
Zhang T, Chen W, Jiang X, et al. Anticancer effects
and underlying mechanism of Colchicine on human
gastric cancer cell lines in vitro and in vivo. Biosci Rep. 2019;39(1).
Liu CY, Liao HF, Shih SC, et al. Colchicine sensitizes
human hepatocellular carcinoma cells to damages
caused by radiation. World J Gastroenterol. 2005;11(27):4237.
Shen J, Zhang Y, Yu H, et al. Role of DUSP1/MKP1
in tumorigenesis, tumor progression and therapy.
Cancer Med. 2016;5(8):2061.
Fakih M, Replogle T, Lehr JE,. Inhibition of prostate
cancer growth by estramustine and colchicine.Prostate. 1995;26(6):310–5.
Maryam A, Mehmood T, Yan Q, et al. Proscillaridin
A Promotes Oxidative Stress and ER Stress, Inhibits
STAT3 Activation, and Induces Apoptosis in A549
Lung Adenocarcinoma Cells. Oxid Med Cell Longev.
Zhu X, Li Z, Li T, et al. Osthole inhibits the PI3K/
AKT signaling pathway via activation of PTEN and
induces cell cycle arrest and apoptosis in esophageal
squamous cell carcinoma. Biomed Pharmacother.
Sarveazad A, Agah S, Babahajian A, et al. Predictors
of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci. 2019;(1).
Kuo MC, Chang SJ, Hsieh MC. Colchicine Significantly Reduces Incident Cancer in Gout Male Patients: Awww.indonesianjournalofcancer.or.id
P-ISSN: 1978-3744 E-ISSN: 2355-6811
Lin ZY, Yeh ML, Huang CI, et al. Potential of novel
colchicine dosage schedule for the palliative
treatment of advanced hepatocellular carcinoma.
Kaohsiung J Med Sci. 2021;37(7):616–23.
Wells RG, Kruglov E, Dranoff JA. Autocrine release
of TGF-β by portal fibroblasts regulates cell growth. FEBS Lett. 2004;559(1–3):107–10.
Sun CK, Chua MS, He J, So SK. Suppression of
Glypican 3 Inhibits Growth of Hepatocellular Carcinoma Cells through Up-Regulation of TGF-β2. Neoplasia. 2011;13(8):735.
Hayashi M, Nomoto S, Kanda M, et al. Identification
of the a kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. J Surg Oncol. 2012;105(4):381–6.
Akakura S, Gelman IH. Pivotal Role of AKAP12 in
the Regulation of Cellular Adhesion Dynamics: Control of Cytoskeletal Architecture, Cell Migration, and Mitogenic Signaling. J Signal Transduct. 2012;2012:1–7.
Liu W, Guan M, Hu T, et al. Re-Expression of AKAP12
Inhibits Progression and Metastasis Potential of Colorectal Carcinoma In Vivo and In Vitro. PLoS One. 2011;6(8):e24015.
Tao T, Ji Y, Cheng C, et al. Tumor necrosis factoralpha inhibits Schwann cell proliferation by upregulating Src-suppressed protein kinase C substrate expression. J Neurochem. 2009;111(3):647–55.
Numajiri A, Mibayashi M, Nagata DK. StimulusDependent and Domain-Dependent Cell Death
Acceleration by an IFN-Inducible Protein, Human MxA. J Interferon Cytokine Res. 2006;26(4):214–9.
Haruki AN, Naito T, Nishie T, Saito S, Nagata K. Interferon-Inducible Antiviral Protein MxA Enhances Cell Death Triggered by Endoplasmic Reticulum Stress.
J Interferon Cytokine Res. 2011;31(11):847–56.
Mushinski JF, Nguyen P, Stevens LM, et al. Inhibition
of Tumor Cell Motility by the Interferon-inducible GTPase MxA. J Biol Chem. 2009 May 29;284(22):15206.
Kask L, Trouw LA, Dahlbäck B, Blom AM. The C4bbinding Protein-Protein S Complex Inhibits the Phagocytosis of Apoptotic Cells. J Biol Chem. 2004;279(23):23869–73.
Trouw LA, Nilsson SC, Gonçalves I, et al. C4b-binding
protein binds to necrotic cells and DNA, limiting
DNA release and inhibiting complement activation.
J Exp Med. 2005;201(12):1937.
Moghadaszadeh B, Beggs AH. Selenoproteins and
Their Impact on Human Health Through Diverse
Physiological Pathways. Physiology (Bethesda). 2006;21(5):307.
Patterson KI, Brummer T, O’Brien PM, Daly RJ. Dualspecificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009;418(3):475–89.
Seternes OM, Kidger AM, Keyse SM. Dual-specificity
MAP kinase phosphatases in health and disease. Biochim Biophys Acta Mol Cell Res. 2019;1866(1):124.
Kidger AM, Keyse SM. The regulation of oncogenic
Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs). Semin Cell Dev Biol. 2016;50:125.
Chen K, Gorgen A, Ding A, et al. Dual-Specificity
Phosphatase 9 Regulates Cellular Proliferation and
Predicts Recurrence After Surgery in Hepatocellular
Carcinoma. Hepatol Commun. 2021;5(7):1310.
Sizemore G, Pitarresi J, Balakrishnan S, et al. The
ETS family of oncogenic transcription factors in solid
tumours. Nat Rev Cancer. 2017;17(6):337–51. 50. Si Y, Liu X, Cheng M, et al. Growth Differentiation Factor 15 Is Induced by Hepatitis C Virus Infection and Regulates Hepatocellular Carcinoma-Related Genes. PLoS One. 2011;6(5):19967.
Sakai T, Balasubramanian K, Maiti S, et al. PlasminCleaved β-2-Glycoprotein 1 Is an Inhibitor of Angiogenesis. Am J Pathol. 2007;171(5):1659.
Davis MW, Wason S. Effect of steady-state atorvastatin on the pharmacokinetics of a single
dose of colchicine in healthy adults under fasted
conditions. Clin Drug Investig. 2014;34(4):259–67.
Frydrychowicz C, Pasieka B, Pierer M, et al. Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report. J Med Case Rep. 2017;11(1):1–5. 54. Oh DHJ, Chan SQ, Wilson AM. Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. Med J Aust. 2012;197(6):332–3.
Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicineinduced acute myopathy in a patient with
concomitant use of simvastatin. Clin Neuropharmacol.
Torgovnick J, Sethi N, Arsura E. Colchicine and HMG
Co-A reductase inhibitors induced myopathy-a case report. Neurotoxicology. 2006;27(6):1126–7.
Tufan A, Sener Dede D, Cavus S, et al. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother. 2006;40(7–8):1466–9.
Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30(6):799–802. 59. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140–6. 12-Year Cohort Study. Medicine (Baltimore). 2015;94(50).
Article MetricsAbstract view : 177 times
PDF - 79 times
- There are currently no refbacks.
Copyright (c) 2022 Indonesian Journal of Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.